| abstract |
An effective prophylactic mucosal gene expression vaccine (GXV) consisting of a mixture of at least four different plasmid DNAs encoding the corresponding RSV antigens and coacervated with chitosan to form nanoparticles is provided. In mouse models of RSV infection, intranasal administration of GXV results in significant induction of RSV-specific antibodies, intranasal IgA antibodies, cytotoxic T lymphocytes, and IFN-γ production in lung and splenocytes Caused by. A single dose of GXV dramatically reduces virus titer. |